Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.45 USD -2.84% Market Closed
Market Cap: 24.7m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Investor Relations

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Yaacov Yanay
President, CEO & Director
No Bio Available
Ms. Liat Zalts
Chief Financial Officer & Treasurer
No Bio Available
Mr. Lior Raviv
Chief Technology Officer
No Bio Available
Dr. Arthur Machlenkin Ph.D.
Chief Scientific Officer
No Bio Available
Ms. Efrat Livne-Hadass
Chief Wellbeing Officer
No Bio Available
Ms. Orly Amiran
Chief Quality Officer
No Bio Available
Ms. Efrat Kaduri
Chief Business Development Officer of Pharma
No Bio Available
Mr. Nimrod Bar Zvi
Chief Commercial Officer
No Bio Available
Mr. John Dvor
EVP North America
No Bio Available

Contacts

Address
Haifa
MATAM Advanced Technology Park, Building #5
Contacts
+972747108600
www.pluristem.com